Concepedia

Author

Frank Gray

GlaxoSmithKline (United Kingdom)

Also Known As

F Gray, F.A. Gray, Frank A Gray, Frank A. Gray, Frank Gray

20

Publications

293

Citations

11

H-Index

11

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)Indivior (United Kingdom)GlaxoSmithKline (Italy)GlaxoSmithKline (United States)GlaxoSmithKline (China)
FG

About

Frank Gray is an author at GlaxoSmithKline (United Kingdom) specializing in immunology, immunotherapy, and molecular pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

34

2

Biochemistry

1

1

34

3

Immunology

1

1

34

4

Pharmacology

1

1

34

5

Clinical Pharmacology

1

1

34

Frank Gray

×

11

Publications

274

Citations

11

H-Index

YearCitations

GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species

A. Richard Rutter, Alessandro Poffe, Palmina Cavallini,

Journal of Pharmacology and Experimental Therapeutics

2014

49

Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study

Joanne Ellis, André van Maurik, Léa Fortunato,

British Journal of Clinical Pharmacology

2018

42

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients

Laurence Moss, Marijke Hyke Algera, Robert L. Dobbins,

PLoS ONE

2022

38

Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine‐1‐phosphate receptor modulator, in healthy volunteers

Jianfeng Xu, Frank Gray, Alex Henderson,

Clinical Pharmacology in Drug Development

2013

34

Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET

Khanum Ridler, Roger N. Gunn, Graham E. Searle,

Journal of Psychopharmacology

2014

24

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder

Ruihua Dong, Hongyun Wang, Dandan Li,

Drugs in R&D

2019

21

Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography

Robert A. Comley, Cristian Salinas, Mark Slifstein,

Journal of Pharmacology and Experimental Therapeutics

2013

20

Pharmacokinetics and central nervous system effects of the novel dual <scp>NK<sub>1</sub>/NK<sub>3</sub></scp> receptor antagonist <scp>GSK</scp>1144814 in alcohol‐intoxicated volunteers

Erik T. te Beek, Justin L. Hay, Jonathan Bullman,

British Journal of Clinical Pharmacology

2012

12

Contribution of SPECT Measurements of D<sub>2</sub>and 5-HT<sub>2A</sub>Occupancy to the Clinical Development of the Antipsychotic SB-773812

Ana M. Catafau, Santiago Bullich, Gianluca Nucci,

Journal of Nuclear Medicine

2011

12

Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double‐blind, placebo‐controlled trial

Xuyi Wang, Haifeng Jiang, Min Zhao,

Asia-Pacific Psychiatry

2018

11

Page 1